Inspire Pharmaceuticals has launched a second Phase 2 clinical trial of its proposed drug for the treatment of cystic fibrosis.

The trial will include 72 people, which will receive either the drug or a placebo three times a day.

Inspire said the second test is needed to develop a better understanding of safety and tolerability of the drug. Two other toxicology studies have been launched as well as Inspire prepares to take the drug to a Phase 3 trial.

The company said it hopes to complete the Phase 3 trial by the end of 2005.